Publications

Nathan, P., Zweifel, M., Padhani, AR., Koh, DM., Ng, M., Collins, DJ., Harris, A., Carden, C., Smythe, J., Fisher, N., et al. (2012) Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer. Clin Cancer Res, Vol.18(12), pp.3428-3439, ISSN: 1078-0432,  Show Abstract

van der Graaf, WTA., Blay, J-Y., Chawla, SP., Kim, D-W., Bui-Nguyen, B., Casali, PG., Schoffski, P., Aglietta, M., Staddon, AP., Beppu, Y., et al. (2012) Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial LANCET, Vol.379(9829), pp.1879-1886, ISSN: 0140-6736,

Pacey, S., Wilson, RH., Walton, M., Eatock, MM., Hardcastle, A., Zetterlund, A., Arkenau, HT., Moreno-Farre, J., Banerji, U., Roels, B., et al. (2011) A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors. Clin Cancer Res, Vol.17(6), pp.1561-1570, ISSN: 1078-0432,  Full Text,  Show Abstract

Olmos, D., Postel-Vinay, S., Molife, LR., Okuno, SH., Schuetze, SM., Paccagnella, ML., Batzel, GN., Yin, D., Pritchard-Jones, K., Judson, I., et al. (2010) Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet Oncol, Vol.11(2), pp.129-135, ISSN: 1474-5488,  Full Text,  Show Abstract

Lee, CP., Payne, GS., Oregioni, A., Ruddle, R., Tan, S., Raynaud, FI., Eaton, D., Campbell, MJ., Cross, K., Halbert, G., et al. (2009) A phase I study of the nitroimidazole hypoxia marker SR4554 using 19F magnetic resonance spectroscopy. Br J Cancer, Vol.101(11), pp.1860-1868,  Full Text,  Show Abstract

O'Donnell, A., Faivre, S., Burris, HA3., Rea, D., Papadimitrakopoulou, V., Shand, N., Lane, HA., Hazell, K., Zoellner, U., Kovarik, JM., et al. (2008) Phase I pharmacokinetic and pharmacodynamic study of oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumours. J Clin Oncol, Vol.10(26), pp.1588-1595, ISSN: 0732-183X,

Pacey, SC., Wilson, RH., Walton, M., Martin, E., Moreno-Farre, J., Arkenau, HT., Steinfeldt, H., Raynaud, F., Workman, P. & Judson, I. (2007) A phase I trial of the heat shock protein 90 (HSP90) inhibitor alvespimycin (17-dimethylaminoethylamino-17-demethoxygeldanamycin 17-DMAG) administered weekly, intravenously, to patients with advanced, solid tumors MOL CANCER THER, Vol.6(12), pp.3332S-3332S, ISSN: 1535-7163,